You are choosing a QA vendor for a product a regulator can inspect, a notified body can audit, and a patient can be harmed by. That changes the question entirely.

Most vendor checklists were not written for you. Search "QA vendor evaluation" and you get call-center quality monitoring, generic test outsourcing, AI governance frameworks, and EHR procurement advice — four different things wearing the same two letters. None of them tells you what to ask a partner who will build the validation evidence your audit depends on.

The questions to ask a healthcare QA vendor all test one thing: whether they can produce defensible evidence under inspection. Ask about BAA flow-down to every sub-processor, IEC 62304 V&V and traceability, 21 CFR Part 11 audit-trail testing, who owns the test assets, and what authority they hold over your release decisions. Everything below is built around those answers.

Choosing a healthcare QA vendor?

16+ years in regulated healthcare. Zero failed regulatory audits. Engineering and QA run as one function, with compliance designed in from the first sprint.

Why the wrong healthcare QA vendor costs more than a failed release

A failed release costs you a sprint. A failed validation costs you the submission.

When QA is wrong in a regulated product, the bill doesn't arrive at release. It arrives at audit, recall, or warning letter — and by then the vendor is gone and the liability is yours.

The pattern is documented. Between 2020 and 2024, the FDA recorded nearly 4,000 medical device recalls out of roughly 200,000 devices it monitors, and software is a named, recurring cause. In 2025, Class I recalls and corrections hit infusion-pump systems including Fresenius Kabi's Ivenix and BD Alaris — the most serious category, tied to risk of serious injury or death.

Validation failures surface in enforcement directly. A March 2025 FDA warning letter to Dexcom cited quality-system violations including process validation, design validation, and CAPA. Those are not exotic findings. They are the everyday output of QA that tested function but never produced evidence.

That is the reframe. A healthcare test automation QA vendor is not selling you green test runs. It is building the proof that you were in control of your software when something went wrong. A vendor's weak evidence becomes your audit finding. Liability does not outsource.

Compliance and data handling: past the BAA logo (Questions 1–3)

Most checklists stop at "make sure they sign a BAA." A signed BAA is the floor, not the answer. The exposure sits one layer down.

Q1: Does the BAA flow down to every sub-processor that touches PHI?

Your vendor signs a BAA with you. Then they route test data through a cloud provider, a logging service, a screenshot tool, an offshore contractor. Each of those is a sub-processor. If the BAA does not flow down to every link that touches protected health information, your chain has a gap — and the gap is yours. Ask for the sub-processor list. Ask how the BAA flows down to each one. A vendor who cannot produce the list has not mapped its own PHI exposure.

Q2: Which certification proves what?

"We're HIPAA compliant" is a claim, not a certificate; there is no HIPAA certification body. What you can verify is audited attestations. SOC 2 Type II shows security controls operated over a period, not a point in time. ISO 27001 covers an information security management system. ISO 13485 covers a medical device quality management system. Each proves one specific thing and leaves the rest unproven.

Certification or claim
What it proves
What it does not prove

SOC 2 Type II

Security controls operated effectively over a defined period

Anything about medical device quality or project-level validation

ISO 27001

A managed information security management system exists

That PHI handling meets HIPAA, or that data stays in-region

ISO 13485

A medical device quality management system is in place

That any specific project's V&V evidence is complete

"HIPAA compliant" (self-claimed)

Nothing on its own — no certification body exists

Sub-processor flow-down, data residency, or audit readiness

Signed BAA

A contractual obligation between you and the vendor

That sub-processors touching PHI are covered

Q3: Where does our data live, and how is GDPR handled for EU clinical data?

Data residency is a contractual and legal question, not a preference. If you handle EU clinical data, you need to know where it is stored, who can access it from which jurisdiction, and how transfers are governed. HIPAA compliant QA testing does not make a vendor GDPR-ready. Ask both, separately, and get the answers in writing.

Regulated validation evidence: the questions no checklist asks (Questions 4–6)

This is the section the generic checklists skip, and the one that decides whether you survive an inspection. Medical device software testing is not "more testing." It is evidence built to a standard, traceable end to end.

Q4: Can you work to IEC 62304 safety classes and produce V&V evidence?

IEC 62304 is the recognized consensus standard for medical device software lifecycle processes. It sorts software into safety classes A, B, and C by the harm a failure could cause, and requires verification and validation appropriate to that class. One correction first: no vendor is "IEC 62304 certified." FDA, EMA, and MHRA issue no such certificate. It is a standard you conform to — recognized across major markets, demonstrated through evidence, not a logo. A vendor that claims the certificate is telling you it does not understand the standard. Ask instead how they classify software, what verification and validation they run per class, and to see the evidence.

Q5: Show me a traceability matrix linking requirements to tests to risk controls.

Ask for a redacted traceability matrix from a comparable project. IEC 62304 expects traceability across requirements, architecture, implementation, testing, and risk controls — every requirement linked to the test that verifies it and the risk control it addresses. A real matrix is dense, owned by a named person, and maps sample to evidence. "We follow best practices" is not a matrix. If they cannot show you one, they have not built one, and you will be building it yourself the week before submission.

Q6: How do you test 21 CFR Part 11 audit trails and electronic signatures?

If your system holds electronic records or signatures under FDA jurisdiction, 21 CFR Part 11 audit-trail testing is not optional. Audit trails must be secure, time-stamped, and attributable; they record who did what and when, and resist alteration. Ask how the vendor tests that the trail captures the right events, that e-signatures bind to the correct records, and that nothing can be silently edited. A vendor who treats this as a routine functional test does not understand what the trail is for.

SaMD validation evidence ties these together. Software as a Medical Device carries the same V&V and traceability burden as embedded device software — sometimes heavier, because the software is the device. A vendor fluent here talks in evidence and standards. A vendor who isn't talks in tooling.

Engagement model and ownership in healthcare QA outsourcing (Questions 7–9)

The most common reason a QA partnership fails is not vendor skill. It is the engagement model. A vendor scoped only to "test what's built" never challenges scope and never influences a release decision — which is exactly the influence a regulated product needs.

Q7: Which model fits — embedded, managed, or full outsourcing — and who decides scope?

Embedded staff augmentation puts healthcare-fluent QA inside your team, under your direction. Managed delivery hands a scoped outcome to the vendor. Full outsourcing moves the whole function. Each has a place. What matters is who owns scope decisions and whether the model lets QA say "this isn't ready" with authority behind it.

Q8: Who owns the test assets, frameworks, and traceability evidence?

This is your audit defense, and it is routinely buried in a contract footnote. Ask in writing who owns the test cases, automation frameworks, and traceability matrix when the engagement ends. If the vendor owns your validation evidence, your audit defense walks out the door with them. The answer should be: you do.

Q9: What does exit and knowledge transfer look like?

Plan the exit before you sign. A regulated product outlives any single vendor relationship, and the next team — yours or another vendor's — inherits the evidence. Ask what transfers, in what format, and how long it takes. "We'll figure it out" means a gap in your design history record when you can least afford one.

How they actually work under deadline (Questions 10–12)

Headcount and certifications tell you what a vendor has. They do not tell you how it behaves the week before a submission, when the schedule is tight and a defect is ambiguous. That behavior is what you are buying.

Q10: How do you identify, prioritize, and communicate risk under deadline?

Risk-based testing is the difference between a vendor that tests everything shallowly and one that tests what matters deeply. Ask how they decide what to test first when time is short, and how they tell you what they chose not to cover. A vendor that can't articulate its risk model is testing on instinct.

Q11: What authority do you have over a release decision, and what's the defect SLA?

A QA function that cannot hold a release has no real authority. Ask what happens when they find a blocking defect and the business wants to ship. Ask the SLA for triage and turnaround on a critical defect. The answers tell you whether QA is a gate or a rubber stamp.

Q12: What is the healthcare domain depth of the people on my account?

Not the company average — the people on your account. A firm can advertise deep healthcare experience and staff your project with generalists. Ask who specifically will work on your product, how many regulated healthcare projects they have shipped, and which standards they have worked under. A QA vendor evaluation checklist that stops at company-level claims misses the only number that touches your code.

The Audit-Survivability Map: from vendor answer to inspection outcome

Every checklist gives you questions. None tells you what a defensible answer must contain, or what it costs you when it's missing. This does. Read each row as: what good sounds like, what disqualifying sounds like, the artifact you must produce in an inspection, and the standard and finding category at stake.

The question
What a defensible answer contains
What a disqualifying answer sounds like
The artifact you must produce in an audit
Standard it maps to / finding risk if absent

Show me a traceability matrix from a comparable project

A redacted real matrix; a named owner; requirements linked to tests and risk controls

"We follow best practices"; a tooling list with no artifact

Traceability matrix

IEC 62304 traceability; gap risks a verification / traceability finding

Prove your V&V approach by safety class

A class-based V&V plan plus executed evidence from a real project

"We run full regression on everything"; no class logic

V&V report and verification records

IEC 62304 V&V by class; design / process validation finding category

How do you test 21 CFR Part 11 controls

Test cases for audit-trail integrity, time-stamping, and e-signature binding

"It's covered in functional testing"

Audit-trail and e-signature test evidence

21 CFR Part 11 audit trail; records-integrity finding category

Does the BAA flow down to every sub-processor

A sub-processor list, documented flow-down, and a data-residency map

"We signed your BAA"

BAA chain / sub-processor register

HIPAA; uncovered PHI exposure

Who owns the test assets on exit

"You do," in writing; a defined transfer format

"That's in the standard terms" / vendor-owned

Transferable test assets in the design history record

ISO 13485 supplier control; gap in design history

What authority do you have over a release

QA can hold a release; a defined critical-defect SLA

"We report; you decide everything"

Release and defect decision records

Quality system / CAPA traceability

The pattern across the table is consistent. Process validation, design validation, and CAPA are repeat citations in real FDA enforcement — the Dexcom warning letter is one public example. The artifacts in the fourth column are not paperwork for its own sake. They are what an investigator or notified body asks to see, and their absence is what a finding is written against. (Specific 483 observation counts vary by inspection and are not assumed here — only the finding categories, which are well documented.)

Which questions to ask a healthcare QA vendor carry the most weight

Not all twelve are equal. Score them as evidence, not enthusiasm.

Green flags: the vendor shows artifacts before you ask twice — a redacted matrix, a V&V report, a sub-processor list. They classify software by risk before they test. They name who owns your test assets without hedging, and the answer is you. They can describe a release they held.

Red flags: answers in adjectives, not evidence. "Best practices," "robust process," "fully compliant," with nothing to show. A claimed IEC 62304 certificate. A BAA presented as the whole compliance story. Account staffing described only as a company average.

The line is simple. A vendor who can produce the artifact survives the audit. A vendor who can only describe the process becomes the finding.

This is the bar to hold every healthcare QA vendor to, including us. At Flyant, engineering and QA run as one function and compliance is designed in from the first sprint rather than retrofitted before submission — part of why the record across 16+ years is zero failed regulatory audits. Whoever you choose, choose for the inspection you will face, not the demo you are watching. The vendor either hands the investigator the evidence, or hands you the finding.

Hold us to all 12 questions

Frequently Asked Questions

Yes, if the vendor or its systems will create, receive, store, or transmit protected health information on your behalf, a BAA is required under HIPAA. The harder question is flow-down: the BAA has to extend to every sub-processor — cloud, logging, contractors — that touches PHI. A signed BAA with the vendor alone does not cover the chain behind it.
Look for audited attestations that map to your need: SOC 2 Type II for security controls over time, ISO 27001 for information security management, and ISO 13485 where a medical device quality system is relevant. None of these proves project-level V&V evidence is complete. There is no HIPAA or IEC 62304 certificate — those are conformance demonstrated through evidence, not a logo.
IEC 62304 is the recognized international standard for medical device software lifecycle processes. It assigns software a safety class — A, B, or C — based on potential harm, and requires verification, validation, and traceability appropriate to that class. For QA, it sets the evidence bar: requirements linked to tests linked to risk controls, end to end. FDA and EU MDR regulators recognize it, though no body issues a formal certificate.
It depends on the gap. In-house QA keeps domain context and control close; embedded or outsourced QA adds regulated-healthcare depth and capacity faster than hiring. The wrong question is which is cheaper. The right one is which model gives QA real authority over your release and clear ownership of the validation evidence.
Pricing varies with engagement model, scope, regulatory burden, and the seniority and domain depth of the people on your account — there is no single rate. The more useful framing is total cost: weigh the engagement against the cost of a software-related medical device recall, a delayed submission, or a warning letter that validation evidence would have prevented.

Didn’t find the answer you are looking for?

Contact us
Dmitry Reznik

Dmitry Reznik

CTO

Dmitry Reznik is the Chief Technology Officer and co-founder at Flyant, where he leads technology across the full delivery lifecycle, from system architecture to production operations. He brings deep technical expertise in building scalable, high-performance healthcare software with quality engineered in from the start, and he shapes the technical decisions that keep complex systems reliable over time.